DEA temporarily places 2-FDCK in Schedule I
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The rule temporarily classifies 2-fluorodeschloroketamine, also known as 2-FDCK, as a Schedule I controlled substance in the United States. That means the substance is treated as having no accepted medical use and a high risk of abuse under federal drug controls. Businesses, laboratories, researchers, importers, exporters, distributors, and anyone else handling 2-FDCK must now follow Schedule I requirements. Unauthorized manufacture, distribution, research, import, export, or possession can trigger federal civil, administrative, and criminal penalties. The order runs from May 22, 2026, to May 22, 2028, unless DEA extends it or makes it permanent.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Temporarily adds 2-FDCK, including covered salts and isomers, to Schedule I of the Controlled Substances Act
- Applies Schedule I controls to manufacturing, distribution, import, export, research, chemical analysis, and possession
- Makes unauthorized handling subject to federal administrative, civil, and criminal penalties
Obligations
What this law requires
Do not manufacture, distribute, reverse distribute, import, export, possess, conduct research with, conduct instructional activities with, or perform chemical analysis on 2-fluorodeschloroketamine (2-FDCK), including its salts, isomers, and salts of isomers, unless authorized under Schedule I controlled substance requirements.
Persons authorized to handle 2-FDCK must comply with all regulatory controls applicable to Schedule I controlled substances under the Controlled Substances Act during the temporary scheduling period.
Entities proposing to handle 2-FDCK must obtain or maintain the required Schedule I authorization before handling the substance.